{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:23:16Z","timestamp":1790673796134,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015070","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000}}],"reference-count":133,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015070.pub2","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T11:09:22Z","timestamp":1666350562000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Topical corticosteroids for dry eye"],"prefix":"10.1002","volume":"2022","author":[{"given":"Su-Hsun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J","family":"Saldanha","sequence":"additional","affiliation":[{"name":"Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice; Brown University School of Public Health; Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison G","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanitsara","family":"Rittiphairoj","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora, CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hauswirth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Gregory","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristos","family":"Ifantides","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"10.1002\/14651858.CD015070.pub2-BIB0001|cit1","first-page":"6753","article-title":"Patients enrichment for increased dendritiform cells using in vivo confocal microscopy results in improved response to topical steroids in dry eye disease: results of the therapeutic response to antiinflammatory agents in the corneal epithelium (TRACE) study","volume":"60","author":"Akhlaq","year":"2019","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0002|cit2","first-page":"5207","article-title":"Change in dendritiform cell density by in vivo confocal microscopy may be used as a surrogate biomarker for therapeutic response in ery eye disease patients enriched for presence of inflammation: results from the therapeutic response to anti-inflammatory","volume":"60","author":"Hamrah","year":"2019","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0003|cit3","unstructured":"Using in vivo confocal microscopy to assess cellular response and efficacy of steroid treatment in ery eye disease clinicaltrials.gov\/ct2\/show\/NCT02106377"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0004|cit4","unstructured":"The utility of IVCM to assess cellular response and efficacy of long-term topical steroid treatment in patients With DED clinicaltrials.gov\/show\/NCT02120079"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"368-76","DOI":"10.5301\/ejo.5000229","article-title":"Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sj\u00f6gren syndrome","volume":"23","author":"Aragona","year":"2013","journal-title":"European Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD015070.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"593-602","DOI":"10.1016\/S0002-9394(03)00326-X","article-title":"The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study","volume":"136","author":"Avunduk","year":"2003","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD015070.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ajo.2004.01.038","article-title":"The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study","volume":"137","author":"Chan","year":"2004","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0008|cit8","unstructured":"Lotemax\u00ae Gel 0.5% and Restasis 0.05% in participants with mild or moderate keratoconjunctivitis sicca (ery eye disease) clinicaltrials.gov\/show\/NCT01817582"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0009|cit9","first-page":"ARVO E-Abstract","article-title":"Efficacy of combined treatment of cyclosporine 0.05% and 1% methylprednisolone on dry eye patients of Sj\u00f6gren syndrome","volume":"48","author":"Byoun","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ICO.0b013e31818c69ef","article-title":"Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye","volume":"31","author":"Byun","year":"2012","journal-title":"Cornea"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0011|cit11","first-page":"516-9","article-title":"Study on the effect of sodium hyaluronate combined with loteprednol eye drops on the treatment of dry eye in children","volume":"18","author":"Cao","year":"2018","journal-title":"International Eye Science"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0012|cit12","first-page":"1825-9","article-title":"Loteprednol combined with sodium hyaluronate in the treatment of dry eye disease and its effect on tnf-\u03b1 and cxcl10 in tears","volume":"34","author":"Chen","year":"2020","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0013|cit13","unstructured":"Safety and efficacy of KPI-121 in subjects with dry eye disease (Kauai) clinicaltrials.gov\/show\/NCT02188160"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0014|cit14","unstructured":"Safety and efficacy of KPI-121 in subjects with dry eye disease clinicaltrials.gov\/show\/NCT02813265"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0015|cit15","unstructured":"Safety and efficacy of KPI-121 compared to placebo in subjects with dry eye disease clinicaltrials.gov\/show\/NCT02819284"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0016|cit16","unstructured":"Safety and efficacy of KPI-121 in subjects with DED clinicaltrials.gov\/show\/NCT03616899"},{"issue":"6","key":"10.1002\/14651858.CD015070.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1172-83. e1","DOI":"10.1016\/j.ajo.2014.08.015","article-title":"Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial","volume":"158","author":"Lee","year":"2014","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0018|cit18","unstructured":"Changes of inflammatory cytokines in the tears of moderate and severe MGD treated with topical loteprednol etabonate clinicaltrials.gov\/show\/NCT01692652"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0019|cit19","first-page":"509-14","article-title":"Effects of fluorometholone combined with sodium hyaluronate eye drops in the treatment of xerophthalmia and the influence on inflammatory factors in tears","volume":"21","author":"Li","year":"2021","journal-title":"International Eye Science"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1097\/MD.0000000000000551","article-title":"Topical fluorometholone treatment for ocular dryness in patients with Sj\u00f6gren syndrome: a randomized clinical trial in China","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0021|cit21","first-page":"377","article-title":"Clinical study of corticosteriod for meibomian gland dysfunction","volume":"13","author":"Luo","year":"2013","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0022|cit22","unstructured":"Evaluation of anti-inflammatory treatment in dry eye patients clinicaltrials.gov\/ct2\/show\/NCT01276223"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"444-57","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"American Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD015070.pub2-BIB0024|cit24","first-page":"397","article-title":"Tear fluid proteome reveals inflammation and immune response proteins as potential predictive biomarkers of the effects of desiccating stress and dry eye treatments","volume":"57","author":"Aapola","year":"2016","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD015070.pub2-BIB0025|cit25","first-page":"2861","article-title":"Tear cytokine biomarkers in dry eye patients subjected to environmental stress and treated with topical 0.1% fluorometholone","volume":"57","author":"Calonge","year":"2016","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ophtha.2016.03.054","article-title":"Re: Pinto-Fraga et al.: topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial","volume":"124","author":"Estevez","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD015070.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"84-92","DOI":"10.1016\/j.jtos.2017.09.003","article-title":"Topical fluorometholone treatment and desiccating stress change inflammatory protein expression in tears","volume":"16","author":"N\u00e4ttinen","year":"2018","journal-title":"Ocular Surface"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0028|cit28","unstructured":"Efficacy and safety of fluorometholone (FML) in dry eye disease (keratoconjunctivitis sicca) clinicaltrials.gov\/show\/NCT02051023"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"368-76","DOI":"10.1016\/j.jtos.2018.05.001","article-title":"Severity, therapeutic, and activity tear biomarkers in dry eye disease: an analysis from a phase III clinical trial","volume":"16","author":"Pinto-Fraga","year":"2018","journal-title":"Ocular Surface"},{"issue":"1","key":"10.1002\/14651858.CD015070.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"141-53","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial","volume":"123","author":"Pinto-Fraga","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0031|cit31","unstructured":"Efficacy of Zylet vs. Lotemax for the treatment of ocular surface inflammation\/MGD\/blepharitis clinicaltrials.gov\/show\/NCT01456780"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ophtha.2014.11.006","article-title":"Effects of corneal nerve density on the response to treatment in dry eye disease","volume":"122","author":"Kheirkha","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0033|cit33","first-page":"291","article-title":"Corneal dendritic cells as a surrogate biomarker of therapeutic efficacy in dry eye-associated corneal inflammation","volume":"56","author":"Qazi","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0034|cit34","unstructured":"Donnenfeld ED Sheppard JD Holland EJ Slonim CH Solomon R Solomon KD Prospective, multicenter, randomized controlled study on the effect of loteprednol etabonate on initiating therapy with cyclosporin A Annual Meeting of American Academy of Ophthalmology; 2007 Nov 10-13; New Orleans (LA) 2007"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0035|cit35","unstructured":"Multicenter, randomized, controlled study of the effect of Lotemax on initiation of dry eye treatment with Restasis clinicaltrials.gov\/show\/NCT00407043"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"289-96","DOI":"10.1097\/ICL.0000000000000049","article-title":"Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%","volume":"40","author":"Sheppard","year":"2014","journal-title":"Eye & Contact Lens"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0037|cit37","first-page":"ARVO E-Abstract","article-title":"Topical loteprednol 0.5% induction therapy improves topical cyclosporine emulsion tolerability in chronic dry eye disease","volume":"49","author":"Sheppard","year":"2008","journal-title":"Investigative Ophthalmology & Vision Science"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/tjo.tjo_15_18","article-title":"Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: a prospective study","volume":"9","author":"Singla","year":"2019","journal-title":"Taiwan Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0039|cit39","first-page":"142-7","article-title":"Study on the treatment of dry eye with loteprednol etabonate","volume":"48","author":"Wan","year":"2012","journal-title":"Zhonghua Yan Ke Za Zhi [Chinese Journal of Ophthalmology]"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1449-57","DOI":"10.1016\/j.ophtha.2016.02.044","article-title":"A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease","volume":"123","author":"Abud","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"299-300","DOI":"10.1016\/j.optm.2010.04.071","article-title":"Loteprednol etabonate 0.2% in the possible treatment of dry eye syndrome","volume":"81","author":"Acord","year":"2010","journal-title":"Optometry"},{"issue":"4","key":"10.1002\/14651858.CD015070.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1167\/iovs.10-6997h","article-title":"The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee","volume":"52","author":"Asbell","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"725-32","DOI":"10.1097\/ICO.0000000000000436","article-title":"Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-a 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation","volume":"34","author":"Boynton","year":"2015","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0044|cit44","unstructured":"0.1% tacrolimus (FK506) in the treatment of moderately severe dry eye clinical efficacy evaluation trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-IPQ-15006773"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0045|cit45","unstructured":"A phase IV, randomized, parallel group, investigator-masked evaluation of the effect of loteprednol etabonate ophthalmic gel 0.5% on the initiation of dry eye treatment with Restasis\u00ae clinicaltrials.gov\/show\/NCT02028312"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0046|cit46","unstructured":"Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sj\u00f6grens' syndrome trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-003391-35-NL"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0047|cit47","unstructured":"A clinical trial to evaluate the safety and efficacy of Pro-ocular\u2122 topical gel in two different concentration, 0.5% and 1%, when administered in the forehead twice a day for 12 weeks in patients diagnosed with dry eye syndrome trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-000747-27-IT"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"251584142110127","DOI":"10.1177\/25158414211012797","article-title":"The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares","volume":"13","author":"Gupta","year":"2021","journal-title":"Therapeutic Advances in Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0049|cit49","unstructured":"Comparison of the treatment effect of preservative-free vs preserved eye drops in patients with dry eye syndrome trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN13765551"},{"issue":"8","key":"10.1002\/14651858.CD015070.pub2-BIB0050|cit50","first-page":"5081-9","article-title":"Antioxidant and inflammatory cytokine in tears of patients with dry eye syndrome treated with preservative-free versus preserved eye drops","volume":"55","author":"Jee","year":"2014","journal-title":"Investigative Ophthalmology & Vision Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0051|cit51","unstructured":"Efficacy of expression treatment on o-MGD (obstructive meibomian gland dysfunction) trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000025159"},{"issue":"1","key":"10.1002\/14651858.CD015070.pub2-BIB0052|cit52","first-page":"329-41","article-title":"Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial","volume":"37","author":"Kallab","year":"2020","journal-title":"Advances in Therapy"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"198-205","DOI":"10.1016\/j.ophtha.2005.09.033","article-title":"Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients","volume":"113","author":"Lee","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0055|cit55","unstructured":"Clinical efficacy of topical hydrocortisone 0.335% (Softacort\u00ae) in patients with chronic dry eye disease and associated ocular surface inflammation clinicaltrials.gov\/show\/NCT03907865"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0056|cit56","first-page":"ARVO E-Abstract","article-title":"Is there a role for a long term tapered small dose steroidal treatment for keratoconjunctivitis sicca?","volume":"49","author":"Rolando","year":"2008","journal-title":"Investigative Ophthalmology & Vision Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0057|cit57","first-page":"ARVO E-Abstract","article-title":"Change of nerve growth factor after 01% prednisolone instillation in dry eye syndrome patients and its correlation with clinical parameters","volume":"46","author":"Ryu","year":"2005","journal-title":"Investigative Ophthalmology & Vision Science"},{"issue":"9","key":"10.1002\/14651858.CD015070.pub2-BIB0058|cit58","first-page":"1633-5","article-title":"Clinical effect of 1g\/L fluorometholone drops combined with soft corneal contact lens for filamentary keratitis","volume":"15","author":"Shen","year":"2015","journal-title":"International Eye Science"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5455\/njppp.2015.5.1601201519","article-title":"Comparative evaluation of topical carboxymethyl cellulose either alone or in combination with topical corticosteroid in the treatment of dry eye in a tertiary-care teaching hospital","volume":"5","author":"Sindhu","year":"2015","journal-title":"National Journal of Physiology, Pharmacy and Pharmacology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0060|cit60","unstructured":"Loteprednol 0.25% (Eysuvis) for dry eye disease Medical Letter on Drugs and Therapeutics 2021 63 1624 75 7"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0061|cit61","unstructured":"Clinical trial of sodium bromide hydrate eye drops and Pranoprofen eye drops for dry eye trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-IPR-15007196"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0062|cit62","first-page":"ARVO E-Abstract","article-title":"Treatment of lid wiper epitheliopathy with a metastable lipid emulsion or a corticosteroid","volume":"46","author":"Herman","year":"2005","journal-title":"Investigative Ophthalmology & Vision Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0063|cit63","unstructured":"Phase II study of AL-2178 (FID 109980) in the treatment of dry eye clinicaltrials.gov\/show\/NCT00471419"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0064|cit64","unstructured":"Loteprednol etabonate ophthalmic suspension for the treatment of dry eye clinicaltrials.gov\/ct2\/show\/NCT00560638"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0065|cit65","unstructured":"Efficacy of nonsteroidal anti-inflammatory drugs in treatment of moderate and severe dry eye disease clinicaltrials.gov\/ct2\/show\/NCT01562795"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0066|cit66","unstructured":"Dry eye disease study with brimonidine clinicaltrials.gov\/show\/NCT03418727"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0067|cit67","unstructured":"Ocular inflammation and dry eye trialsearch.who.int\/?trialid=NTR2291"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0068|cit68","unstructured":"Eye drops made of antibodies for dry eye disease patients trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/02\/031182"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0069|cit69","unstructured":"Evaluation of the performance of new substitute tears in dry eye patients trialsearch.who.int\/?TrialID=ISRCTN16288419"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0070|cit70","unstructured":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid\/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease clinicaltrials.gov\/show\/NCT04734197"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0071|cit71","unstructured":"A research study to see how well an eye drop, SURF-200 (0.02% and 0.04% Betamethasone Sodium Phosphate), works, what side effects there are, and to compare it with vehicle (placebo) in subjects diagnosed with dry eye disease and experiencing an episodic flare-up clinicaltrials.gov\/show\/NCT04734210"},{"issue":"7066","key":"10.1002\/14651858.CD015070.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015070.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","article-title":"The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study","volume":"136","author":"Avunduk","year":"2003","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0074|cit74","first-page":"3826","article-title":"The effect of tapered small dose steroidal treatment on symptoms, clinical signs, and ocular surface inflammation in patients with dry eye syndrome","volume":"52","author":"Barabino","year":"2011","journal-title":"Investigative Ophthalmology & Vision Science"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/jop.2020.0014","article-title":"Loteprednol etabonate for the treatment of dry eye disease","volume":"36","author":"Beckman","year":"2020","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD015070.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/ije\/dyu080","article-title":"What is the difference between missing completely at random and missing at random?","volume":"43","author":"Bhaskaran","year":"2014","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocular Surface"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ICO.0b013e31818c69ef","article-title":"Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye","volume":"31","author":"Byun","year":"2012","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0080|cit80","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"4","key":"10.1002\/14651858.CD015070.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14656566.2018.1439920","article-title":"Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid","volume":"19","author":"Comstock","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0082|cit82","unstructured":"Covidence Veritas Health Innovation"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09273948.2017.1341988","article-title":"The use of topical corticosteroids for treatment of dry eye syndrome","volume":"27","author":"Cutolo","year":"2019","journal-title":"Ocular Immunology and Inflammation"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0084|cit84","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.exer.2006.02.004","article-title":"Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye","volume":"83","author":"De Paiva","year":"2006","journal-title":"Experimental Eye Research"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1167\/iovs.05-1281","article-title":"Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline","volume":"47","author":"De Paiva","year":"2006","journal-title":"Investigative Ophthalmology and Vision Science"},{"issue":"9","key":"10.1002\/14651858.CD015070.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051.pub2","article-title":"Topical cyclosporine A therapy for dry eye syndrome","author":"De Paiva","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD015070.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaophthalmol.2013.4503","article-title":"Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire","volume":"131","author":"Sakane","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD015070.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011016.pub2","article-title":"Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease","author":"Downie","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015070.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006775.pub3","article-title":"Punctal occlusion for dry eye syndrome","author":"Ervin","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0091|cit91","unstructured":"Evans DG Sheppard JD Williams JI Loteprednol etabonate ophthalmic gel 0.5% for inflammation associated with dry eye disease: outcomes of a 12-week Phase 2 clinical study Annual Meeting of the American Optometric Association; 2017 Sep 27-30; Washington, DC 2017"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocular Surface"},{"issue":"11","key":"10.1002\/14651858.CD015070.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0094|cit94","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0095|cit95","unstructured":"Higgins JPT Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jtos.2019.02.012","article-title":"Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review","volume":"17","author":"Holland","year":"2019","journal-title":"Ocular Surface"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1167\/iovs.11-8284","article-title":"Standardized assessment of reading performance: the New International Reading Speed Texts IReST","volume":"53","author":"Trauzettel-Klosinski","year":"2012","journal-title":"International Ophthalmology and Vision Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00006324-200212000-00007","article-title":"Asymptomatic corneal staining associated with the use of balafilcon silicone-hydrogel contact lenses disinfected with a polyaminopropyl biguanide-preserved care regimen","volume":"79","author":"Jones","year":"2002","journal-title":"Optomery and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocular Surface"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0100|cit100","unstructured":"Kojima T Dogru M Kawashima M Nakamura S Tsubota K Advances in the diagnosis and treatment of dry eye Progress in Retinal and Eye Research 10.1016\/j.preteyeres.2020.100842"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"198e205","DOI":"10.1016\/j.ophtha.2005.09.033","article-title":"Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients","volume":"113","author":"Lee","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00006324-198912000-00008","article-title":"Psychophysics of reading: VIII. The Minnesota low-vision reading test","volume":"66","author":"Legge","year":"1989","journal-title":"Optometry and Vision Science"},{"issue":"1","key":"10.1002\/14651858.CD015070.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.ico.0000240079.24583.a1","article-title":"Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model","volume":"26","author":"Lekhanont","year":"2007","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0104|cit104","unstructured":"Lemp MA Report of the National Eye Institute\/Industry Workshop on clinical trials in dry eyes CLAO Journal 1995 21 211 32"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0105|cit105","unstructured":"Li T Higgins JPT Deeks JJ Chapter 5: Collecting data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0161-6420(00)00101-9","article-title":"A standardized visual scale for evaluation of tear fluorescein clearance","volume":"107","author":"Macri","year":"2000","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0107|cit107","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"1","key":"10.1002\/14651858.CD015070.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtos.2017.05.005","article-title":"TFOS DEWS II Introduction","volume":"15","author":"Nelson","year":"2017","journal-title":"Ocular Surface"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2017.05.024","article-title":"Brand medications and Medicare Part D: how eye care providers' prescribing patterns influence costs","volume":"125","author":"Newman-Casey","year":"2018","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD015070.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","article-title":"Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire","volume":"32","author":"Ngo","year":"2013","journal-title":"Cornea"},{"issue":"7","key":"10.1002\/14651858.CD015070.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1167\/iovs.16-19419","article-title":"Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments","volume":"57","author":"Nichols","year":"2016","journal-title":"Investigative Ophthalmology and Vision Science"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/978-1-4615-5359-5_113","article-title":"Sensitivity and specificity of a screening questionnaire for dry eye","volume":"438","author":"Oden","year":"1998","journal-title":"Advances in Experimental Medicine Biology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0114|cit114","unstructured":"Page MJ Higgins JPT Sterne JAC Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009327.pub3","article-title":"Autologous serum eye drops for dry eye","author":"Pan","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009729.pub2","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","author":"Pucker","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/ICO.0b013e3181fb84ea","article-title":"Age-related variations of human tear meniscus and diagnosis of dry eye with Fourier-domain anterior segment optical coherence tomography","volume":"30","author":"Qiu","year":"2011","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0119|cit119","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"12","key":"10.1002\/14651858.CD015070.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1097\/ICO.0000000000001350","article-title":"Gaps in current knowledge and priorities for future research in dry eye","volume":"36","author":"Saldanha","year":"2017","journal-title":"Cornea"},{"issue":"10","key":"10.1002\/14651858.CD015070.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaophthalmol.2018.3352","article-title":"Research questions and outcomes prioritized by patients with dry eye","volume":"136","author":"Saldanha","year":"2018","journal-title":"JAMA Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD015070.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0123|cit123","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604.ch14"},{"issue":"26","key":"10.1002\/14651858.CD015070.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-019-1290-z","article-title":"Prevalence and associated risk factors of dry eye disease in 16 northern West bank towns in Palestine: a cross-sectional study","volume":"20","author":"Shanti","year":"2020","journal-title":"BMC Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD015070.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 Phase 3 Study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Clinical Trial"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12950-017-0174-3","article-title":"Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome","volume":"14","author":"Shih","year":"2017","journal-title":"Journal of Inflammation (London)"},{"issue":"3","key":"10.1002\/14651858.CD015070.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocular Surface"},{"issue":"1","key":"10.1002\/14651858.CD015070.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/dtb.2016.1.0378","article-title":"The management of dry eye","volume":"54","author":"Stephenson","year":"2016","journal-title":"Drug and Therapeutics Bulletin"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0130|cit130","unstructured":"WebPlotDigitizer Rohatgi A"},{"key":"10.1002\/14651858.CD015070.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II Diagnostic Methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocular Surface"},{"issue":"4","key":"10.1002\/14651858.CD015070.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu","year":"2011","journal-title":"Cornea"},{"issue":"9","key":"10.1002\/14651858.CD015070.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015070","article-title":"Topical corticosteroids for dry eye","author":"Liu","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:04:53Z","timestamp":1762146293000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015070.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":133,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015070.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}